Polyanion induced fibril growth enables the development of a reproducible assay in solution for the screening of fibril interfering compounds, and the investigation of the prion nucleation site

Amyloid

Volumn 14, Issue 3, 2007, Pages 205-219

  Boshuizen, Ronald S ^a   Morbin, Michela ^b   Mazzoleni, Giulia ^b   Tagliavini, Fabrizio ^b   Meloen, Rob H ^a,c   Langedijk, Johannes P M ^a  

^a Pepscan Systems   (Netherlands)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Amyloid; BSE; CJD; GAG; Prion

Indexed keywords

ALANINE; DOXYCYCLINE; HEPARIN; HISTIDINE; LYSINE; MECLOCYCLINE; MINOCYCLINE; OXYTETRACYCLINE; POLYANION; PRION PROTEIN; PROLINE; ROLITETRACYCLINE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; VALINE;

AMINO ACID SUBSTITUTION; ARTICLE; BETA SHEET; FIBER; FLUORESCENCE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING;

AMINO ACID SEQUENCE; AMYLOID; BIOLOGICAL ASSAY; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; POLYMERS; PRIONS; PROTEIN STRUCTURE, SECONDARY;

EID: 34547855876     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.1080/13506120701464628     Document Type: Article

References (62)

1. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982;216:136-144.
2. Jeffrey M, Goodsir CM, Bruce ME, McBride PA, Fraser JR. In vivo toxicity of prion protein in murine scrapie. ultrastructural and immunogold studies. Neuropathol Appl Neurobiol 1997;23:93-101.
3. Peyrin JM, Lasmezas CI, Haik S, Tagliavini F, Salmona M, Williams A, Richie D, Deslys JP, Dormont D. Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines. Neuroreport 1999;10:723-729.
4. Bate C, Reid S, Williams A. Killing of prion-damaged neurones by microglia. Neuroreport 2001;12:2589-2594.
5. Bruce ME, McBride PA, Farquhar CF. Precise targeting of the pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie. Neurosci Lett 1989;102:1-6.
6. Gray F, Chretien F, Adle-Biassette H, Dorandeu A, Ereau T, Delisle MB, Kopp N, Ironside JW, Vital C. Neuronal apoptosis in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol 1999;58:321-328.
7. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration. separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003;26:267-298.
8. Novitskaya V, Bocharova OV, Bronstein I, Baskakov IV. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J Biol Chem 2006;281:13828-13836.
9. Serpell LC, Sunde M, Blake CC. The molecular basis of amyloidosis. Cell Mol Life Sci 1997;53:871-887.
10. Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, Caughey B. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol 2003;77:10288-10294.
11. Kocisko DA, Engel AL, Harbuck K, Arnold KM, Olsen EA, Raymond LD, Vilette D, Caughey B. Comparison of protease-resistant prion protein inhibitors in cell cultures infected with two strains of mouse and sheep scrapie. Neurosci Lett 2005;388:106-111.
12. Breydo L, Bocharova OV, Baskakov IV. Semiautomated cell-free conversion of prion protein. applications for high-throughput screening of potential antiprion drugs. Anal Biochem 2005;339:165-173.
13. Maxson L, Wong C, Herrmann LM, Caughey B, Baron GS. A solid-phase assay for identification of modulators of prion protein interactions. Anal Biochem 2003;323:54-64.
14. Bocharova OV, Breydo L, Parfenov AS, Salnikov VV, Baskakov IV. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc). J Mol Biol 2005;346:645-659.
15. Baskakov IV, Legname G, Baldwin MA, Prusiner SB, Cohen FE. Pathway complexity of prion protein assembly into amyloid. J Biol Chem 2002;277:21140-21148.
16. Sokolowski F, Modler AJ, Masuch R, Zirwer D, Baier M, Lutsch G, Moss DA, Gast K, Naumann D. Formation of critical oligomers is a key event during conformational transition of recombinant syrian hamster prion protein. J Biol Chem 2003;278:40481-40492.
17. Swietnicki W, Morillas M, Chen SG, Gambetti P, Surewicz WK. Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. Biochemistry 2000;39:424-431.
18. Leffers KW, Wille H, Stohr J, Junger E, Prusiner SB, Riesner D. Assembly of natural and recombinant prion protein into fibrils. Biol Chem 2005;386:569-580.
19. Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, Tagliavini F. Neurotoxicity of a prion protein fragment. Nature 1993;362:543-546.
20. Salmona M, Malesani P, De Gioia L, Gorla S, Bruschi M, Molinari A, Della Vedova F, Pedrotti B, Marrari MA, Awan T, Bugiani O, Forloni G, Tagliavini F. Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126. Biochem J 1999;342 (Pt 1):207-214.
21. De Gioia L, Selvaggini C, Ghibaudi E, Diomede L, Bugiani O, Forloni G, Tagliavini F, Salmona M. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J Biol Chem 1994;269:7859-7862.
22. Jobling MF, Stewart LR, White AR, McLean C, Friedhuber A, Maher F, Beyreuther K, Masters CL, Barrow CJ, Collins SJ, Cappai R. The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106-126. J Neurochem 1999;73:1557-1565.
23. Florio T, Paludi D, Villa V, Principe DR, Corsaro A, Millo E, Damonte G, D'Arrigo C, Russo C, Schettini G, Aceto A. Contribution of two conserved glycine residues to fibrillogenesis of the 106-126 prion protein fragment. Evidence that a soluble variant of the 106-126 peptide is neurotoxic. J Neurochem 2003;85:62-72.
24. Boshuizen RS, Langeveld JP, Salmona M, Williams A, Meloen RH, Langedijk JP. An in vitro screening assay based on synthetic prion protein peptides for identification of fibrilinterfering compounds. Anal Biochem 2004;333:372-380.
25. Sellarajah S, Lekishvili T, Bowring C, Thompsett AR, Rudyk H, Birkett CR, Brown DR, Gilbert IH. Synthesis of analogues of Congo red and evaluation of their anti-prion activity. J Med Chem 2004;47:5515-5534.
26. Caughey B, Caughey WS, Kocisko DA, Lee KS, Silveira JR, Morrey JD. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics. A common mechanism for anti-TSE compounds? Acc Chem Res 2006;39:646-653.
27. Bertsch U, Winklhofer KF, Hirschberger T, Bieschke J, Weber P, Hartl FU, Tavan P, Tatzelt J, Kretzschmar HA, Giese A. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets. J Virol 2005;79:7785-7791.
28. Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, Girola L, Bertani I, Poli G, Caramelli M, Grazia Bruzzone M, Farina L, Limido L, Rossi G, Giaccone G, Ironside JW, Bugiani O, Salmona M, Tagliavini F. Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A 2002;99:10849-10854.
29. Tagliavini F, Forloni G, Colombo L, Rossi G, Girola L, Canciani B, Angeretti N, Giampaolo L, Peressini E, Awan T, De Gioia L, Ragg E, Bugiani O, Salmona M. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 2000;300:1309-1322.
30. Soto C, Kindy MS, Baumann M, Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun 1996;226:672-680.
31. Soto C, Kascsak RJ, Saborio GP, Aucouturier P, Wisniewski T, Prelli F, Kascsak R, Mendez E, Harris DA, Ironside J, Tagliavini F, Carp RI, Frangione B. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000;355:192-197.
32. Langedijk JP, Fuentes G, Boshuizen R, Bonvin AM. Two-rung model of a left-handed beta-helix for prions explains species barrier and strain variation in transmissible spongi-form encephalopathies. J Mol Biol 2006;360:907-920.
33. Govaerts C, Wille H, Prusiner SB, Cohen FE. Evidence for assembly of prions with left-handed beta-helices into trimers. Proc Natl Acad Sci U S A 2004;101:8342-8347.
34. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R, Eisenberg D. Structure of the cross-beta spine of amyloid-like fibrils. Nature 2005;435:773-778.
35. Caughey B, Brown K, Raymond GJ, Katzenstein GE, Thresher W. Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red [corrected]. J Virol 1994;68:2135-2141.
36. Castillo GM, Lukito W, Wight TN, Snow AD. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem 1999;72:1681-1687.
37. Jenkins J, Pickersgill R. The architecture of parallel beta-helices and related folds. Prog Biophys Mol Biol 2001;77:111-175.
38. Klajnert B, Cortijo-Arellano M, Bryszewska M, Cladera J. Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer's and prion diseases. Biochem Biophys Res Commun 2006;339: 577- 582.
39. Nandi PK, Leclerc E. Polymerization of murine recombinant prion protein in nucleic acid solution. Arch Virol 1999;144:1751-1763.
40. Yang DS, Serpell LC, Yip CM, McLaurin J, Chrishti MA, Horne P, Boudreau L, Kisilevsky R, Westaway D, Fraser PE. Assembly of Alzheimer's amyloid-beta fibrils and approaches for therapeutic intervention. Amyloid J Protein Fold Dis 2001;8 Suppl 1:10-19.
41. Wong C, Xiong LW, Horiuchi M, Raymond L, Wehrly K, Chesebro B, Caughey B. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. Embo J 2001;20:377-386.
42. Deleault NR, Geoghegan JC, Nishina K, Kascsak R, Williamson RA, Supattapone S. Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J Biol Chem 2005;280:26873-26879.
43. Pan T, Wong BS, Liu T, Li R, Petersen RB, Sy MS. Cellsurface prion protein interacts with glycosaminoglycans. Biochem J 2002;368:81-90.
44. Warner RG, Hundt C, Weiss S, Turnbull JE. Identification of the heparan sulfate binding sites in the cellular prion protein. J Biol Chem 2002;277:18421-18430.
45. Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989;9:21-32.
46. Gonzalez-Iglesias R, Pajares MA, Ocal C, Espinosa JC, Oesch B, Gasset M. Prion protein interaction with glycosaminoglycan occurs with the formation of oligomeric complexes stabilized by Cu(II) bridges. J Mol Biol 2002;319:527-540.
47. Aronoff-Spencer E, Burns CS, Avdievich NI, Gerfen GJ, Peisach J, Antholine WE, Ball HL, Cohen FE, Prusiner SB, Millhauser GL. Identification of the Cu2+ binding sites in the N-terminal domain of the prion protein by EPR and CD spectroscopy. Biochemistry 2000;39:13760-13771.
48. Walter ED, Chattopadhyay M, Millhauser GL. The affinity of copper binding to the prion protein octarepeat domain. evidence for negative cooperativity. Biochemistry 2006;45:13083-13092.
49. Bocharova OV, Breydo L, Salnikov VV, Baskakov IV. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils. Biochemistry 2005;44:6776-6787.
50. Ricchelli F, Buggio R, Drago D, Salmona M, Forloni G, Negro A, Tognon G, Zatta P. Aggregation/fibrillogenesis of recombinant human prion protein and Gerstmann-Straussler-Scheinker disease peptides in the presence of metal ions. Biochemistry 2006;45:6724-6732.
51. Gaggelli E, Bernardi F, Molteni E, Pogni R, Valensin D, Valensin G, Remelli M, Luczkowski M, Kozlowski H. Interaction of the human prion PrP(106-126) sequence with copper(II), manganese(II), and zinc(II). NMR and EPR studies. J Am Chem Soc 2005;127:996-1006.
52. Haik S, Peyrin JM, Lins L, Rosseneu MY, Brasseur R, Langeveld JP, Tagliavini F, Deslys JP, Lasmezas C, Dormont D. Neurotoxicity of the putative transmembrane domain of the prion protein. Neurobiol Dis 2000;7:644-656.
53. Fields CG, Lloyd DH, Macdonald RL, Otteson KM, Noble RL. HBTU activation for automated Fmoc solid-phase peptide synthesis. Pept Res 1991;4:95-101.
54. Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT, Jr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation. implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A 1995;92:763-767.
55. Familian A, Boshuizen RS, Eikelenboom P, Veerhuis R. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia 2006;53: 233-240.
56. Farquhar CF, Dickinson AG. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol 1986;67 (Pt 3):463-473.
57. Kimberlin RH, Walker CA. Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob Agents Chemother 1986;30:409-413.
58. McBride PA, Wilson MI, Eikelenboom P, Tunstall A, Bruce ME. Heparan sulfate proteoglycan is associated with amyloid plaques and neuroanatomically targeted PrP pathology throughout the incubation period of scrapie-infected mice. Exp Neurol 1998;149:447-454.
59. Perez M, Wandosell F, Colaco C, Avila J. Sulphated glycosaminoglycans prevent the neurotoxicity of a human prion protein fragment. Biochem J 1998;335 (Pt 2):369-374.
60. Gasset M, Baldwin MA, Lloyd DH, Gabriel JM, Holtzman DM, Cohen F, Fletterick R, Prusiner SB. Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. Proc Natl Acad Sci U S A 1992;89:10940-10944.
61. Petty SA, Adalsteinsson T, Decatur SM. Correlations among morphology, beta-sheet stability, and molecular structure in prion peptide aggregates. Biochemistry 2005;44:4720-4726.
62. Kretzschmar HA, Stowring LE, Westaway D, Stubblebine WH, Prusiner SB, Dearmond SJ. Molecular cloning of a human prion protein cDNA. Dna 1986;5:315-324.